The anti-HER2 monoclonal antibody pertuzumab may be effective in androgen-independent prostate cancer.
DeGrendele
Heather
H
D000726:Androgen Antagonists / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000911:Antibodies, Monoclonal; D018719:Erb-b2 Receptor Tyrosine Kinases